Oramed Pharmaceuticals Inc (ORMP)
Oramed Pharmaceuticals Inc. is a NASDAQ-listed common stock company focused on pharmaceutical research and development. The company is working on a technology platform designed to deliver therapeutic proteins orally, rather than through conventional injection-based methods. Its lead candidate, ORMD-0801, is an oral insulin capsule being evaluated in phase III clinical trials for people with diabetes. Oramed also has license agreements with Oravax Medical Inc. covering the commercialization of oral vaccines for COVID-19 and other novel coronaviruses. Founded in 2002, the company is headquartered in New York, New York.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ORMP
|
$6.07
|
45.6% Upside
|
Undervalued
|
$6.25
|
50.0% Upside
|
Bargain
|
Good
|
—
|
—
|
0.25
|
0.0%
|
August 12, 2026
|
1.6x
|
0.7x
|
—
|
167.8 M
|
87.616 M
|
0.5%
|
77.2%
|
2.9
|
9.4%
|
-7.8%
|
